Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Neuropharmacology. 2011 May 27;61(4):778–788. doi: 10.1016/j.neuropharm.2011.05.024

Figure 4. Effect of AM251 and AM630 on TRPV1 and TRPA1-mediated responses.

Figure 4

(A) Co-treatments of TG neurons (for 2 min) with Veh+CAP (100 nM), AM251 (25μM)+CAP and AM630 (25μM)+CAP have no-effect on overall [Ca2+]i accumulation, n = 24–38. (B) Pre-treatment (for 5 min) of cultured TG neurons with AM630 (25 μM), but not AM251 (25 μM) attenuated CAP (100 nM)-evoked [Ca2+]i accumulation. CAP was applied for 1 min. Wash times between antagonists and CAP applications are 2 min, n=31–41; error bars = SEM **p<0.01. (C) Ca2+ accumulation generated by WIN55, 212–2 (WIN; 25 μM) and mustard oil (MO; 25μM) pre-treated with vehicle or indicated concentrations of AM251, n=22–68; NS is non-significant. (D) Ca2+ accumulation generated by WIN (25 μM) and MO (25μM) pre-treated with vehicle or indicated concentrations of AM630, n=22–60; error bars = SEM **p<0.01.